SCHEMBL1699519

SCHEMBL1699519

CCOC(=O)C(OCc1ccc(OC)cc1)c1c(C)c(Br)c2ccccc2c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.38
MEN1 O00255 4/20 0.38
MAPT P10636 4/20 0.38
TDP1 Q9NUW8 4/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.38
HKDC1 Q2TB90 2/20 0.38
HPGD P15428 2/20 0.38
CCR6 P51684 1/20 0.38
ALOX5 P09917 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 2/20 0.36
MAPK1 P28482 2/20 0.36
RAB9A P51151 2/20 0.36
ATM Q13315 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1699498 0.81 PSEN1 (0.44) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL1699290 0.80 L3MBTL1 (0.38) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL1699428 0.77 MAPT (0.39) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL1699756 0.77 ADORA3 (0.42) KMT2AMEN1MAPTALDH1A1NPSR1
SCHEMBL1699312 0.73 ALOX15 (0.39) KMT2AMEN1ALDH1A1LMNAL3MBTL1
SCHEMBL7069557 0.69 LMNA (0.52) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL1699478 0.67 CCR2 (0.39) KMT2AMEN1ALDH1A1LMNAL3MBTL1
SCHEMBL17901116 0.67 ATM (0.60) KMT2AMEN1TDP1ALDH1A1KDM4E
SCHEMBL19726540 0.67 ATM (0.60) KMT2AMEN1TDP1ALDH1A1KDM4E
SCHEMBL14945154 0.66 LMNA (0.51) KMT2AMEN1MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588450-B1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES INC (US) 2017-05-24 EP disclosed
EP-2588450-B1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES INC (US) 2017-05-24 EP disclosed
US-9102614-B2 Naphth-2-ylacetic acid derivatives to treat AIDS GILEAD SCIENCES, INC. (US) 2015-08-11 US disclosed
US-9102614-B2 Naphth-2-ylacetic acid derivatives to treat AIDS GILEAD SCIENCES, INC. (US) 2015-08-11 US disclosed
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2013-08-08 US disclosed
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2013-08-08 US disclosed
EP-2588450-A1 NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS Gilead Sciences, Inc. (US) 2013-05-08 EP disclosed
WO-2012003497-A1 NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed
WO-2012003497-A1 NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203727-A1 NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS NFATC1, AADAT, ACAT1 KMT2A 375/4885MEN1 4061/4885MAPT 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.